Generic Drugs Market in Japan 2015-2019

日本のジェネリック医薬品市場2015-2019

◆タイトル:Generic Drugs Market in Japan 2015-2019
◆商品コード:IRTNTR5244
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年2月11日
◆ページ数:94
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:日本
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、日本のジェネリック医薬品市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、日本のジェネリック医薬品市場規模及び予測、製品別分析、市場シェア、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Generic Drugs
A generic drug is a duplicate of brand-name drugs and has the same dosage form, active ingredient(s), potency, route of administration, quality, and intended use as that of branded drugs. Generic drugs enter the market once the patent protection of the original developer expires. Generally, the cost of generic drugs is 50-70 percent lower than that of their brand-name counterparts, while meeting the very same standards of safety, quality, and efficacy as the innovator drugs. Generic drugs help the manufacturer by eliminating the need to develop and market a new drug. As the patent approaches expiration, manufacturers can apply to the FDA for approval to manufacture and sell generic versions of the drug. Generic drugs are equal to and within the bioequivalence range of branded drugs.

TechNavio’s analysts forecast the Generic Drugs market in Japan to grow at a CAGR of 8.16 percent over the period 2014-2019.

[Covered in this Report]
The Generic Drugs market in Japan can be divided into three segments: Generic Prescription Medicines, Super Generics, and Biosimilars. This report covers the present scenario and the growth prospects of the Generic Drugs market in Japan for the period 2015–2019. To calculate the market size, the report considers the revenue generated from the following segments:

• Generic Prescription Medicines
• Super Generics
• Biosimilars

TechNavio’s report, the Generic Drugs market in Japan 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape of the Generic Drugs market in Japan and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Vendors]
• Meiji Seika Pharma
• Nichi-Iko Pharmaceutical
• Nipro Pharma
• Sawai Pharmaceuticals
• Teva Pharmaceutical Industries
• Towa Pharmaceutical

[Other Prominent Vendors]
• Actavis
• Daiichi Sankyo
• Daito Pharmaceutical
• Eisai
• Fuji Pharma
• GlaxoSmithKline
• Hikari Pharmaceutical
• Hospira
• Mylan
• Nihon Generic
• Nippon Chemipher
• Nippon Kayaku
• Nissin Pharmaceutical
• Ohara Pharmaceutical
• Pfizer
• Sandoz
• Taiyo Yakuhin
• Takeda Pharmaceutical
• Zensei Pharmaceutical Industries

[Market Driver]
• Increase in Number of Patent Expiries
• For a full, detailed list, view our report.

[Market Challenge]
• Intense Competition among Vendors
• For a full, detailed list, view our report

[Market Trend]
• Increase in M&A
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Introduction

06.Country Overview of Japan

07.Approval Pathway of Generic Drugs in Japan
07.1 Master File Scheme for Active Ingredients
07.2 Equivalency Review
07.3 Conformity Audit

08.Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis

09.Market Segmentation by Product Category

10.Market Segmentation by Therapeutic Application

11.Buying Criteria

12.Market Growth Drivers

13.Drivers and their Impact

14.Market Challenges

15.Impact of Drivers and Challenges

16.Market Trends

17.Trends and their Impact

18.Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2014
18.3 Other Prominent Vendors

19.Key Vendor Analysis
19.1 Meiji Seika Pharma
19.1.1 Key Facts
19.1.2 Business Description
19.1.3 Business Segmentation
19.1.4 Business Strategy
19.1.5 Revenue by Business Segmentation
19.1.6 Revenue Comparison 2011 and 2012
19.1.7 Revenue by Geographical Segmentation
19.1.8 Key Information
19.1.9 SWOT Analysis
19.2 Nichi-Iko
19.2.1 Key Facts
19.2.2 Business Description
19.2.3 Business Segmentation
19.2.4 Business Strategy
19.2.5 Revenue by Business Segmentation
19.2.6 Revenue Comparison 2011 and 2012
19.2.7 Revenue by Geographical Segmentation
19.2.8 Key Information
19.2.9 SWOT Analysis
19.3 Nipro Pharma
19.3.1 Key Facts
19.3.2 Business Description
19.3.3 Business Segmentation
19.3.4 Business Strategy
19.3.5 Revenue by Business Segmentation
19.3.6 Revenue Comparison 2011 and 2012
19.3.7 Revenue by Geographical Segmentation
19.3.8 Key Information
19.3.9 SWOT Analysis
19.4 Sawai
19.4.1 Key Facts
19.4.2 Business Description
19.4.3 Business Segmentation
19.4.4 Business Strategy
19.4.5 Revenue by Business Segmentation
19.4.6 Revenue Comparison 2011 and 2012
19.4.7 Revenue by Geographical Segmentation
19.4.8 Key Information
19.4.9 SWOT Analysis
19.5 Teva Pharmaceutical Industries
19.5.1 Key Facts
19.5.2 Business Description
19.5.3 Business Segmentation
19.5.4 Business Strategy
19.5.5 Revenue by Business Segmentation
19.5.6 Revenue Comparison 2011 and 2012
19.5.7 Revenue by Geographical Segmentation
19.5.8 Key Information
19.5.9 SWOT Analysis
19.6 Towa Pharmaceutical
19.6.1 Key Facts
19.6.2 Business Description
19.6.3 Business Segmentation
19.6.4 Business Strategy
19.6.5 Revenue by Business Segmentation
19.6.6 Revenue Comparison 2011 and 2012
19.6.7 Revenue by Geographical Segmentation
19.6.8 Key Information
19.6.9 SWOT Analysis

20.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Country Overview of Japan
Exhibit 3: Main Data Required for Generic Drugs Approval
Exhibit 4: Generic Drugs Market in Japan Overview
Exhibit 5: Generic Drugs Market in Japan 2014-2019 (US$ billion)
Exhibit 6: Parameters to Promote the Use of Generic Drugs Ahead
Exhibit 7: Generic Drug Market Share of Japan in 2014 (in percent)
Exhibit 8: Generic Drugs Market Share of Japan in 2019 (in percent)
Exhibit 9: Generic Drugs Market Share of Japan and Global (US$ billion)
Exhibit 10: Generic Drugs Market Segmentation by Product Category
Exhibit 11: Generic Drugs Market in Japan by Therapeutic Applications
Exhibit 12: Patent Expiration of Branded Drugs in Japan
Exhibit 13: Medical Costs in Japan (in thousand billion)
Exhibit 14: Price Difference of atorvastatin between Originator and Generic in Japan (US$)
Exhibit 15: Trends of Aging Population in Japan (in percentage)
Exhibit 16: Reviews Conducted for Generic Drugs and Others by Fiscal Year 2008-2012
Exhibit 17: Comparison between Applications Filed and Approval in Japan
Exhibit 18: Meiji Seika Pharma: Business Segmentation by Revenue 2013
Exhibit 19: Meiji Seika Pharma: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 20: Meiji Seika Pharma: Geographical Segmentation
Exhibit 21: Nichi-Iko: Business Segmentation by Revenue 2013
Exhibit 22: Nichi-Iko: Business Segmentation by Revenue 2012 and 2013
Exhibit 23: Nichi-Iko: Geographical Segmentation by Revenue 2013
Exhibit 24: Nipro Pharma: Business Segmentation by Revenue 2013
Exhibit 25: Nipro Pharma: Business Segmentation by Revenue 2012 and 2013
Exhibit 26: Nipro Pharma: Geographical Segmentation by Revenue 2013
Exhibit 27: Sawai: Business Segmentation by Revenue 2013
Exhibit 28: Sawai: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 29: Sawai: Geographical Segmentation
Exhibit 30: Teva Pharmaceutical Industries: Business Segmentation by Revenue 2013
Exhibit 31: Teva Pharmaceutical Industries: Business Segmentation by Revenue 2012 and 2013
Exhibit 32: Teva Pharmaceutical Industries: Geographical Segmentation by Revenue 2013
Exhibit 33: Towa Pharmaceutical: Business Segmentation by Revenue 2013
Exhibit 34: Towa Pharmaceutical: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 35: Towa Pharmaceutical: Geographical Segmentation



【掲載企業】

Meiji Seika Pharma, Nichi-Iko Pharmaceutical, Nipro Pharma, Sawai Pharmaceuticals, Teva Pharmaceutical Industries, Towa Pharmaceutical, Actavis, Daiichi Sankyo, Daito Pharmaceutical, Eisai, Fuji Pharma, GlaxoSmithKline, Hikari Pharmaceutical,Hospira, Mylan, Nihon Generic, Nippon Chemipher, Nippon Kayaku, Nissin Pharmaceutical, Ohara Pharmaceutical, Pfizer, Sandoz, Taiyo Yakuhin, Takeda Pharmaceutical, Zensei Pharmaceutical Industries

【資料のキーワード】

ジェネリック医薬品(後発医薬品)、日本

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[日本のジェネリック医薬品市場2015-2019] (Generic Drugs Market in Japan 2015-2019 / IRTNTR5244)販売に関する免責事項
[日本のジェネリック医薬品市場2015-2019] (Generic Drugs Market in Japan 2015-2019 / IRTNTR5244)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆